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doi:10.1016/j.ejvs.2010.04.010Abstract Aim: The durability of occlusion post endovenous laser therapy (EVLT) for varicose
veins is linked to the magnitude of energy delivered to the vein and consequently increasing
amounts of energy are employed. The aim of this study is to establish whether increasing
the energy results in greater periprocedural morbidity or complications.
Methods: Linear and logistic regression models were built to study the effect of energy
delivery on outcome. The models controlled for age, gender, BMI, pre-operative quality of life
and vein dimension. The outcomes were pain and analgesia requirement in week 1, change in
disease specific quality of life (Aberdeen varicose vein questionnaire (AVVQ), change in generic
quality of life (Short Form-36 (SF-36) and Euroqol (EQ5D)at week 1 and 6 and complication
rates. The sample size calculation established that 115 patients would be required to detect
any significant relationship.
Results: 232 patients were included. The mean (range) age was 50 (18e83) years. 63% were
women. The mean (range) energy delivery was 89.8 (44.5e158.4) J/cm. There was no signif-
icant effect on any outcome related to increasing energy delivery.
Conclusion: Up to 160J/cm, increasing energy delivery has no significant effect upon the
morbidity or complications of EVLT for superficial venous insufficiency.
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Endovenous laser therapy (EVLT) is a relatively new, but
popular and promising treatment for varicose veins.1e11 A
meta-analysis suggests that EVLT produces significantly
better saphenous ablation on ultrasonography up to 3 yearsd by Elsevier Ltd. All rights reserved.
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frequency ablation.12 There is however still room for
improvement as treatment failure on duplex ultrasonog-
raphy still occurs in 1 of 20 saphenous trunks treated.
Residual and recurrent disease negates someof the quality of
life benefit of treatment and is unpopular with patients.
Davies found that 71% of patientswant full treatment of their
varicose veins in a single visit and over 90% are concerned
about the risk of recurrence.13
Several independent research groups have established
the magnitude of energy delivery to be the most important
predictor of success14e16 and increasing energy delivery has
resulted in improved occlusion rates.17,18 Commonly energy
deliveries of around 20e60 J/cm or equivalent fluence
calculations have been used, but the current best evidence
points to improved results at energies higher than this and
many providers now use 80e100 J/cm. Despite this, 100%
success remains an elusive goal. The reluctance to increase
energy delivery further is most likely due to concerns that
this may result in increased morbidity and complications
from the procedure. There is however, no evidence that
this is the case, when EVLT is performed using tumescent
anaesthetic solution.
Surgeons within our department have been gradually
increasing the energy density utilised since the advent of
EVLT and deliveries of >100 J/cm are now the norm. The
aim of this paper is to establish whether there is any
evidence that increasing the energy density has any effect
upon post-procedural pain, quality of life or complication
rates.Methods
This data is taken from the EVLT arms of non-blinded
randomised controlled trials (NCT00759434 and
NCT00841178)9,10,19 and non-randomised pilot study6 which
was approved by the local research ethics committee and
the institutional research and development department.
Patients presenting to a single tertiary referral vascular
surgical department with symptomatic varicose veins were
assessed for suitability for trial participation.
Inclusion criteria were primary, symptomatic, unilateral
varicose veins, with isolated sapheno-femoral junction
(SFJ) or sapheno-popliteal junction (SPJ) incompetence,
leading to great saphenous vein (GSV) or small saphenous
vein reflux respectively on venous duplex with a vein
diameter 3 mm. Incompetence was defined as reflux 1 s
on spectral-Doppler analysis.
Exclusion criteria were deep venous incompetence on
duplex and inability to give informed consent to trial
participation.
Patients were included in the studies after giving
informed written consent. All EVLT procedures were per-
formed under local tumescent anaesthesia in a dedicated
procedure room within the outpatients department.
Patients were marked pre-operatively using duplex ultra-
sound. Skin preparation and draping were performed prior
to percutaneous cannulation of the GSV or the small
saphenous vein with the patient in the reverse Trendelen-
burg position. Cannulation was performed at the lowest
point of demonstrable reflux. A 5F catheter was introducedinto the vein using the Seldinger technique, and its tip was
accurately positioned at the SFJ/SPJ using ultrasound. The
patient was then placed in the Trendelenburg position, and
perivenous tumescent local anaesthetic infiltrated along
the vein. Total local anaesthetic did not exceed the rec-
ommended maximum safe dose per patient. A sterile bare-
tipped 600 mm laser fibre was introduced via the catheter
for laser ablation of the GSV. Endovenous laser energy was
delivered using an 810 nm diode laser generator
(Angiodynamics, Queensbury, NY, USA).
Surface varicosities and incompetent perforators were
marked pre-operatively in the dependant position and
concomitant phlebectomies were performed via stab inci-
sions made over varicose tributaries, which were avulsed
using a Kocherised mosquito clip or vein hook. These inci-
sions were then closed with Steri-strips (3M, MN, USA).
Perforators were divided and ligated through a 1.5 cm
incision, which was then closed using an absorbable sub-
cuticular suture. Cotton wool, gauze and elastic compres-
sion dressings were then applied. These were later
replaced by a 20e30 mm Hg full-length medical compres-
sion stocking. Compression was applied for 6 weeks in total.
Patients were discharged with analgesics (diclofenac 50 mg
tds) to be taken regularly for 1 week and paracetamol 1g
qds for breakthrough pain.
All patients were seen immediately pre- and post-op by
the same research nurse, who provided the same instruc-
tions: elevation of the leg whilst at rest, mobilise as much
as possible and return to work as soon as they feel able to
do so, avoid driving, returning only when they can safely
perform emergency manoeuvres and after discussion with
their insurers (A time period of 2 weeks was suggested). A
24 h contact number was also given for advice or help.
Post-operative assessment was performed at 1 week and
6 weeks in a dedicated clinic.Outcomes
Patients were given a diary in which to record daily visual
analogue pain scores for the first post-operative week. The
scales consisted of 7 unmarked 10 cm long lines labelled at
one end as “No pain at all” (Score 0) and “Worst Imaginable
Pain” at the other (Score 10). Patients marked these lines
with a cross and this position was measured and recorded to
the nearest millimetre.
In the same diary, patients noted the quantity of
breakthrough analgesic medication required daily for the
first week and the exact time taken to return to normal
activities and to work in days.
Quality of life was measured 1 week and 6 weeks post-
operatively, and the pre-operative scores subtracted to
give a change in QoL at each time point. The instruments
used were as follows:
Generic QoL; SF-36, which utilises 36 items to derive 8
domains each scored from 0 (worst possible) to 100 (best
possible). The 4 physical domains were analysed; Physical
function, Physical Role, Bodily Pain and General health.
Generic QoL; EQ5D, which transforms responses to 5
domain questions, into a global index using a time trade off
tariff, scored on a scale of 0.5 (worst score) to 1.0 (best
score).
Table 1 Clinical and quality of life measures at baseline, 1 week and 6 weeks post-procedure. Median values given with inter-
quartile ranges in parentheses. VCSS is the venous clinical severity score, AVVQ is the Aberdeen varicose vein questionnaire,
EQ5D is the Euroqol generic quality of life instrument and SF-36 the Short Form 36 generic quality of life instrument.
Baseline 1 Week 6 Weeks
VCSS 4 (3e5) N/A N/A
AVVQ 12.9 (9.9e17.8) 16.8 (12.8e21.8) 8.1 (4.7e12.9)
EQ5D 0.80 (0.76e1.00) 0.78 (0.71e1.00) 1.00 (0.80e1.00)
SF-36 Physical Function 90 (75e100) 85 (70e95) 95 (80e100)
SF-36 Physical e Role 100 (50e100) 75 (0e100) 100 (75e100)
SF-36 Bodily Pain 74 (51e84) 74 (51e84) 84 (62e100)
SF-36 General Health 77 (60e90) 77 (67e92) 82 (67e92)
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patients with varicose veins20e29 and generic quality of life
should be used to as both a measure of efficacy and the
morbidity of varicose vein treatment.
Disease Specific QoL; Aberdeen Varicose Veins Question-
naire (AVVQ). This instrument has been shown to be reliable,
valid and responsive23,25,29 and records the specific impact of
venous disease on patient’s quality of life and is scored from
0 (no impact) to a theoretical maximum of 100.
Post-operative complications were noted during clinic
follow-up. Particular problems where were sought included
sensory disturbance, phlebitis, pigmentation, infection,
haematoma and symptoms suggestive of deep vein throm-
bosis (DVT).
Analysis
All data was recorded into a secure dedicated database
(Microsoft Access, Redmond, WA, USA) and analysis per-
formed utilising SPSS (Chicago, IL, USA). Data was analysed
through the construction of linear and logistic regression
models.
As stated above, the outcome measures were post-
procedural pain and analgesia requirement, QoL and
complication rates. The primary predictor variable of
interest was the linear energy delivery in Joules per centi-
metre (J/cm). The other independent predictor variables
were age, gender, body mass index, the radius and length of
the treated vein and pre-operative QoL (Aberdeen varicose
vein questionnaire, EQ5D and physical domains of SF-36).Table 2 Results of the linear regression model charting the ef
scores on a visual analogue scale and return to work and normal
Median (IQR) Score
Day of treatment 1.7 (0.3e4.9)
Day 1 1.2 (0e3.0)
Day 2 0.6 (0e2.1)
Day 3 0.2 (0e1.5)
Day 4 0.3 (0e1.3)
Day 5 0.2 (0e1.5)
Day 6 0 (0e1.0)
Return to: Work 4 (1e11)
Normal activity 3 (1e14)These were includedwithin themodels, so their effect could
be controlled. Some authors calculate energy delivery taking
into account both length and diameter. Controlling for the
radius within these models allows these results to be
comparable. Although the QoL outcomes are the change in
scores, rather than the absolute scores post-procedure,
baseline scores were entered into themodel. This is because
it was unknown whether differing scores at baseline would
respond with differing magnitudes to treatment. For
example would a patient with chronic back pain notice
a similar incremental change in their total bodily pain score
as someone with no pain at all before EVLT? This effect,
where present, was therefore also controlled.
Linear regression models were produced for continuous
outcomes. If the continuous outcomes were not normally
distributed, they were transformed using standard mathe-
matical techniques. Statistical significance was set at
<0.050 (a Z 0.05). T-tests of the estimated b values
allowed significance level calculation of the contribution of
an individual predictor to the model’s predictive ability.
Effect sizes and the proportion of variance in the outcome
due to the energy delivery alone were calculated. The
models were produced via the method of “forced entry.”
This allows the retention of methodological control of the
modal and is thought to reduce the effect of random
sampling variation within the data and produce replicable
results.30 All predictor variables are continuous, with
a variance >0. All outcomes are continuous, independent
and not constrained. No significant multicollinearity was
observed and there are no known correlations between
these predictors and external variables. Residual valuesfect of linear energy delivery (J/cm) on post-operative pain
activity in days.
Effect size Proportion of Variance (R2) P value
0.16 2.69% NS
0.15 2.16% NS
0.06 0.38% NS
0.05 0.29% NS
0.03 0.07% NS
0.07 0.52% NS
0.08 0.61% NS
0.18 3.39% NS
0.11 1.23% NS
Table 3 Results of the logistic regression model charting the effect of linear energy delivery (J/cm) on the proportion of
patients requiring breakthrough supplementary analgesia.
% Requiring supplemental analgesia Odds Ratio (95% CI) P value
Day of Treatment 64.6 1.002 (0.995e1.031) NS
Day 1 45.5 1.016 (0.998e1.033) NS
Day 2 32.1 1.002 (0.984e1.021) NS
Day 3 21.5 1.009 (0.986e1.032) NS
Day 4 17.2 1.005 (0.981e1.030) NS
Day 5 18.7 1.010 (0.987e1.034) NS
Day 6 14.4 1.005 (0.979e1.032) NS
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Residual value histograms were drawn confirming normal
distribution. Finally the independence of errors was
established using the Durbin-Watson test. As 11 predictor
variables are to be studied, the required sample size to test
the individual predictors is 115 and 138 is required to test
the models.31
Logistic regression models were produced for binary
outcomes. In this case the individual contribution of the
predictors is assessed by chi squared testing of the Wald
statistic. The Odds ratio (95% confidence interval) was calcu-
lated for the effect of energy delivery alone on the outcome.
As with linear regression, the “forced entry” method was
used; linearity of the logit and the independence of errorswas
confirmed. Sufficient data was available for all combinations
of variables and multicollinearity was excluded.Results
232 patients are included in this analysis. The mean (range)
age was 50 (18e83) years. 63% were women. The mean
(range) energy delivery was 89.8 (44.5e158.4) J/cm. The
mean (range) diameter of the vein segment treated was 7.4
(3.0e16.4) mm (assuming uniformity). There was no
statistical difference between the energy given to men or
women pZ 0.404 (t-test) and therefore no further gender-
specific analysis was performed. Baseline clinical severity
scores and quality of life are shown in Table 1.
There is no statistically significant relationship between
the energy and the magnitude of post-procedural painTable 4 Results of the linear regression model charting the effe
of life. SF-36 is Short Form-36, AVVQ is the Aberdeen varicose ve
Change in domain Week Effec
SF-36 Physical Function 1 0.0
SF-36 Physical Role 0.0
SF-36 Bodily Pain 0.0
SF-36 General Health 0.1
SF-36 Physical Function 6 0.1
SF-36 Physical Role 0.1
SF-36 Bodily Pain 0.1
SF-36 General Health 0.1
AVVQ 1 0.0
6 0.1
EQ5D 1 0.0
6 0.0(Table 2), or the requirement for supplementary analgesia
(Table 3) during the first week.
Increasing energy also has no effect upon the number of
days taken to return to work or to other activities (Table 2).
At 6 weeks, patients receiving higher energy deliveries
score higher on the AVVQ. This was of borderline statistical
significance (p Z 0.050). There is an effect size of 0.18,
accounting for 3.1% of the variance at this time point. There
wasnosignificant relationship at 1weekand increasingenergy
has no effect upon the post-procedural generic QoL (Table 4).
Complications were uncommon and therefore were
insufficient to allow meaningful further detailed analysis
(Table 5).Discussion
This is the first paper to look in depth upon the effects of
the magnitude of energy delivery upon the morbidity of
EVLT. One would expect that increasing the magnitude of
energy delivery to the vein would increase the magnitude
of tissue damage created, increasing both pain and
swelling, alongside analgesia requirement. This should then
have an impact upon quality of life, reducing mobility and
general health perception. Patients would take longer to
recover. Moreover, transmission of thermal energy beyond
the vein should, in theory damage surrounding structures
resulting in higher complication rates.
Our data does not support this theorem (within the
range of energy utilized). Increasing energy had no effect
upon pain or analgesia requirements. The effect of energyct of linear energy delivery (J/cm) on post-procedural quality
in questionnaire and EQ5D is the Euroqol instrument.
t Size Proportion of Variance (R2) P value
6 0.40% NS
5 0.27% NS
8 0.62% NS
3 1.80% NS
6 2.59% NS
6 2.56% NS
3 1.56% NS
2 1.35% NS
6 0.40% NS
8 3.10% NS
6 0.35% NS
8 0.58% NS
Table 5 Complications rates.
Sensory Disturbance 3.7%
Phlebitis 2.1%
Pigmentation 1.7%
Infection 1.2%
Haematoma 0.4%
DVT 0.0%
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significance and doubtful clinical significance; energy
accounts for just 3.1% of the variation. We have previously
found that generic QoL analysis is more sensitive to the QoL
changes associated with periprocedural morbidity than
AVVQ9 and yet there was no difference seen in either of the
instruments analysed. It follows therefore that there was
no effect upon recovery times. The sample size used in this
analysis is double that required for testing the significance
of an individual predictor, and so it is unlikely that any
significant relationship has been missed.
Complication rates were low, supporting the evidence
that EVLT is a very safe procedure.12,32,33
We believe that our results are explained by the use of
tumescent local anaesthetic. Accurate and meticulous
infiltration of local anaesthetic around the vein causes
hydro-dissection of the surrounding tissues away from the
vein and the laser fibre. This fluid collapses the vein around
the fibre and acts as a heat sink, reducing the transmission
of thermal energy by convection and conduction beyond
the vein wall. The 810 nm photons from this laser are
primarily absorbed by haemoglobin within the blood,34
minimizing the transmission of radiant energy beyond the
vein, also trapping the heat where it is needed: inside the
vein. This may not be the case with longer wavelengths,
which are primarily absorbed by water, and may therefore
be transmitted to the heat sink and possibly beyond.
One criticism of this study is that although all patients
underwent some concomitant treatment (phlebectomy and/
or perforator ligation), the extent of these procedures could
not be controlled between individuals. However, these
procedures maximize the quality of life benefits of treatment
and achieves the much desired aim of one-stop treat-
ment.10,35,36 This study therefore aims to reflect true clinical
practicewith theaimofallowing the results tobegeneralized.
Conclusion
In experienced hands EVLT is safe and effective. Using an
810 nm laser, increasing linear energy delivery up to 160 J/
cm from currently accepted levels appears safe and results
in no measurable additional post operative morbidity.
Studies now need to focus upon the optimal energy
required to result in 100% closure rates and achieve durable
one-stop treatment, first time, every time.
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